{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:15:15Z","timestamp":1776158115448,"version":"3.50.1"},"reference-count":10,"publisher":"PAGEPress Publications","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>Dear Editor,\nScleromyxedema is known as a rare, severe mucinosis with characteristic waxy skin papules along with sclerodermiform induration of the skin and rare systemic manifestations. Monoclonal gammopathy of undetermined significance (MGUS; mostly monoclonal immunoglobulin G [IgG] type lambda) can be detected in up to 90% of patients. [...]<\/jats:p>","DOI":"10.4081\/dr.2026.10557","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:25:47Z","timestamp":1776155147000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment of scleromyxedema Arndt-Gottron with a novel intravenous immunoglobulin preparation"],"prefix":"10.4081","author":[{"given":"Niklas","family":"Negele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia K.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander H.","family":"Enk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"39189","doi-asserted-by":"crossref","unstructured":"1. Hoffmann JHO, Enk AH. Scleromyxedema. J Dtsch Dermatol Ges 2020;18:1449-67.","DOI":"10.1111\/ddg.14319"},{"key":"39190","doi-asserted-by":"crossref","unstructured":"2. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001;44:273-81.","DOI":"10.1067\/mjd.2001.111630"},{"key":"39191","doi-asserted-by":"crossref","unstructured":"3. Mecoli CA, Talbot CC, Fava A, et al. Clinical and Molecular Phenotyping in Scleromyxedema Pretreatment and Posttreatment With Intravenous Immunoglobulin. Arthritis Care Res (Hoboken) 2020;72:761-7.","DOI":"10.1002\/acr.23908"},{"key":"39192","doi-asserted-by":"crossref","unstructured":"4. Harper RA, Rispler J. Lichen Myxedematosus Serum Stimulates Human Skin Fibroblast Proliferation. Science 1978;199:545-7.","DOI":"10.1126\/science.622555"},{"key":"39193","unstructured":"5. Ferrarini M, Helfrich DJ, Walker ER, et al. Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol 1989;16:837-41."},{"key":"39194","unstructured":"6. Yaron M, Yaron I, Yust I, Brenner S. Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 1985;12:171-5."},{"key":"39195","doi-asserted-by":"crossref","unstructured":"7. Karim A, Lawlor F, Black MM. Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin. Clin Exp Dermatol 2004;29:317-8.","DOI":"10.1111\/j.1365-2230.2004.01518.x"},{"key":"39196","doi-asserted-by":"crossref","unstructured":"8. Feldmeyer L, Benden C, Haile S, et al. Not All Intravenous Immunoglobulin Preparations are Equally Well Tolerated. Acta Derm Venereol 2010;90:494-7.","DOI":"10.2340\/00015555-0900"},{"key":"39197","doi-asserted-by":"crossref","unstructured":"9. Ch\u00e9rin P, Cabane J. Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use. BioDrugs 2010;24:211-23.","DOI":"10.2165\/11537660-000000000-00000"},{"key":"39198","doi-asserted-by":"crossref","unstructured":"10. Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol 2004;136:111-3.","DOI":"10.1111\/j.1365-2249.2004.02412.x"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10557\/9925","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10557\/9925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:25:57Z","timestamp":1776155157000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":10,"URL":"https:\/\/doi.org\/10.4081\/dr.2026.10557","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,14]]}}}